From now until October 9, the campaign will support more than 300 women’s shelters and programs across Canada

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) — In Canada every five minutes a woman experiences intimate partner violence1, yet approximately 700 women and children are turned away from shelters each day.2 These stark realities underscore the urgent need for safe spaces and resources for women experiencing abuse.

This September, join Shoppers Foundation for Women’s Health™ in supporting more than 300 women’s shelters and programs across Canada by donating to the Giving Shelter campaign. Shoppers Drug Mart® and Pharmaprix® stores nationwide are raising funds for local organizations to help women and children find safety and take steps toward a life free from abuse.

“Gender-based violence is far more prevalent in Canada than many people realize,” says Paulette Minard, Director of Community Investment and Shoppers Foundation for Women’s Health. “This is a national issue and Giving Shelter is a national campaign, but the funds raised stay within the local community, giving Canadians an opportunity to help neighbours and friends who may be fleeing violence.”

From now until October 9, customers can participate in the fundraising campaign by rounding up their purchase total at checkout at any Shoppers Drug Mart or Pharmaprix store across the country. One hundred percent of donations remain in the communities where they are raised, helping local organizations provide women and children with the safety, services and resources they need.

“Safety changes everything. When a woman experiencing abuse reaches out for help, she needs to know there is somewhere safe to turn,” says Kim Ruse, CEO of FearIsNotLove, one of the local charities being supported this year. “Giving Shelter is more than a fundraising campaign – it is our community saying that violence in our homes matters, and that no woman or family should face it alone. Through Giving Shelter, we can come together to provide the support women and families need to move toward safety and healing, and ultimately a life free from violence and abuse.”

This year’s campaign will also offer Canadians a special opportunity to make their support go even further. From September 25 to 27, Shoppers Foundation for Women’s Health will match funds raised through in-store round up and online donations, up to a total of $150,000, helping generate even more support for local women’s shelters and programs.

To donate or to learn more about Giving Shelter, visit shoppersfoundation.ca.

_______________
1 Statistics Canada, The Daily Trends in police-reported family violence and intimate partner violence in Canada, 2025 
2 Women’s National Housing and Homelessness Network, Global News, November 2024 

About Shoppers Foundation for Women’s Health™

Shoppers Foundation for Women’s Health™ – the charitable arm of Shoppers Drug Mart® – is committed to helping Canadian women lead healthier lives, by making care more equitable and accessible. In 2022, the Foundation set an ambitious goal: to contribute $50M by 2026 towards women’s health initiatives that are making care more equitable and accessible. This milestone has been surpassed, ahead of schedule, and Shoppers Foundation remains steadfast in its commitment to build a future in which more women in Canada can lead healthier lives.” Learn more at shoppersfoundation.ca.

About Shoppers Drug Mart Inc.

Shoppers Drug Mart Inc. is one of the most recognized and trusted names in Canadian retailing. The company is the licensor of full-service retail drug stores operating under the name Shoppers Drug Mart® (Pharmaprix® in Québec). With more than 1,350 Shoppers Drug Mart® and Pharmaprix® stores operating in prime locations in each province and two territories, the company is one of the most convenient retailers in Canada. The company also licenses or owns more than 150 medical clinic pharmacies operating under the name Shoppers Simply Pharmacy® (Pharmaprix Simplement Santé® in Québec). In addition to its retail store network, the company owns Shoppers Drug Mart Specialty Health Network Inc., a provider of specialty drug distribution, pharmacy and comprehensive patient support services, MediSystem Inc., a provider of pharmaceutical products and services to long-term care facilities and Lifemark Health Group, Canada’s leading provider of outpatient physiotherapy, massage therapy, occupational therapy, chiropractic, mental health, and other ancillary rehabilitation services. Shoppers Drug Mart® is an independent operating division of Loblaw Companies Limited.

For all media inquiries, contact: pr@loblaw.ca. 

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Challenger Gold Limited (ASX: CEL; OTCQX: CLLEF), a gold and copper exploration company, has qualified to trade on the OTCQX® Best Market. Challenger Gold Limited upgraded to OTCQX from the OTCQB® Venture Market.

Challenger Gold Limited begins trading today on OTCQX under the symbol “CLLEF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors.

“Our graduation to the OTCQX Best Market is an important milestone and reflects Challenger Gold’s commitment to expanding its presence in North American capital markets. We believe the OTCQX quotation will enhance our visibility with U.S. investors, broaden market participation, and contribute to increased liquidity in our shares. This is also an important step in our strategy to access additional trading platforms and a wider pool of institutional investors as we advance the Hualilán Gold Project toward commercial production,” said Yohann Bouchard, Interim Chief Executive Officer of Challenger Gold Limited.

Trading in Asia Pacific securities on the OTC Markets reached U.S. $19.49B in the second quarter of 2026, representing a 34.1% increase over Q2 2025. OTC Markets recorded U.S. $453.34B in total dollar volume in the first half of the year. Australia ranked among the top home markets by trading volume during the quarter, highlighting sustained U.S. investor demand for internationally listed names.

About Challenger Gold Limited
Challenger Gold Limited engages in the exploration of gold, silver, and copper deposits. Its flagship project is the Hualilan Gold project that comprise 15 mining leases and an exploration license application covering an area of 26 square kilometers located in San Juan, Argentina.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™ Basic Market and Pink Limited™ Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN, OTC Link NQB, OTC Overnight® and MOON ATS® are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

COLUMBUS, Ohio, Sept. 15, 2026 (GLOBE NEWSWIRE) — Bread Financial Holdings, Inc. (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and saving solutions to millions of U.S. consumers, provided a performance update. The following tables present the Company’s Net principal loss rate and Delinquency rate for the periods indicated:

  For the
month ended
August 31, 2026
  For the
month ended
August 31, 2025
  (dollars in millions)
End-of-period credit card and other loans $ 18,730     $ 17,657  
Average credit card and other loans $ 18,588     $ 17,598  
Year-over-year change in average credit card and other loans   5.6 %     (0.9 %)
Net principal losses $ 101     $ 113  
Net principal loss rate   6.40 %     7.57 %

  As of
August 31, 2026
  As of
August 31, 2025
  (dollars in millions)
30 days + delinquencies – principal $ 885     $ 934  
Period ended credit card and other loans – principal $ 16,512     $ 16,001  
Delinquency rate   5.36 %     5.84 %


About Bread Financial
®

Bread Financial®(NYSE: BFH) is a tech-forward financial services company that provides simple, personalized payment, lending and saving solutions to millions of U.S. consumers. Our payment solutions deliver growth for some of the most recognized brands in travel and entertainment, specialty apparel, health and beauty, jewelry, sporting goods, technology and electronics, as well as home and furniture through our co-brand and private label credit cards and pay-over-time products providing choice and value to our shared customers. Additionally, we offer Bread Financial general purpose credit cards and saving products that empower our customers and their passions for a better life.​

Bread Financial proudly marks 30 years of success in 2026. To learn more about our global associates, our performance and our sustainability progress, visit breadfinancial.com or follow us on Instagram and LinkedIn.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements give our expectations or forecasts of future events and can generally be identified by the use of words such as “believe,” “expect,” “anticipate,” “estimate,” “intend,” “project,” “plan,” “likely,” “may,” “should” or other words or phrases of similar import. Similarly, statements that describe our business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements we make regarding, and the guidance we give with respect to, our anticipated operating or financial results, future financial performance and outlook, future dividend declarations, and future economic conditions.

We believe that our expectations are based on reasonable assumptions. Forward-looking statements, however, are subject to a number of risks and uncertainties that are difficult to predict and, in many cases, beyond our control. Accordingly, our actual results could differ materially from the projections, anticipated results or other expectations expressed in this release, and no assurances can be given that our expectations will prove to have been correct. Factors that could cause the outcomes to differ materially include, but are not limited to, the following: macroeconomic conditions, including inflation, interest rates, labor market conditions, financial and capital market conditions, recessionary pressures or concerns over a prolonged economic slowdown, and the related impact on consumer spending behavior, payments, debt levels, savings rates and other behaviors; global political events and conditions, including significant shifts in trade policy, such as changes to, or the imposition of, tariffs and/or trade barriers and consequently any economic impacts, volatility, uncertainty and geopolitical instability resulting therefrom, as well as ongoing wars and military conflicts, and international tensions or hostilities; local or global public health issues, climate-related events, impacts to the power grid, and natural disasters; future credit performance, including the level of future delinquency and charge-off rates; loss of, or reduction in demand for services and/or products from, significant brand partners or customers in the highly competitive markets in which we operate, including competition from new and non-traditional competitors, such as financial technology companies, and with respect to new products, services and technologies, such as the emergence or increase in popularity of agentic commerce, digital payment platforms and currencies and other alternative payment and deposit solutions; the concentration of our business in U.S. consumer credit; inaccuracies in the models and estimates on which we rely, including our credit risk management models and the amount of our Allowance for credit losses; the inability to realize the intended benefits of acquisitions, dispositions and other strategic initiatives; our level of indebtedness and ability to access financial or capital markets; pending and future federal and state legislation, executive action, regulation, supervisory guidance, and regulatory and legal actions, including, but not limited to, those related to financial regulatory reform and consumer financial services practices, as well as any such actions that would place limits on credit card interest rates or late fees, interchange fees or other charges; failures or breaches in our operational or security systems, including as a result of cyberattacks, unanticipated impacts from technology modernization projects or otherwise; and any liability or other adverse impacts arising out of or related to the spinoff of our former LoyaltyOne segment or the bankruptcy filings of Loyalty Ventures Inc. (LVI) and certain of its subsidiaries, including the pending litigation against us in connection with the spinoff. The foregoing factors, along with other risks and uncertainties that could cause actual results to differ materially from those expressed or implied in forward-looking statements, are described in greater detail under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the most recently ended fiscal year, which may be updated in Item 1A of, or elsewhere in, our Quarterly Reports on Form 10-Q filed for periods subsequent to such Form 10-K. Our forward-looking statements speak only as of the date made, and we undertake no obligation, other than as required by applicable law, to update or revise any forward-looking statements, whether as a result of new information, subsequent events, anticipated or unanticipated circumstances or otherwise.

Contacts
Brian Vereb — Investor Relations
Brian.Vereb@breadfinancial.com

Susan Haugen — Investor Relations
Susan.Haugen@breadfinancial.com

Rachel Stultz — Media
Rachel.Stultz@breadfinancial.com

45% objective response rate and 88% disease control rate observed in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, a difficult-to-treat population with no approved targeted therapies

BH-30643 demonstrated a favorable safety profile with low rates of dose reduction or discontinuation due to treatment-related adverse events

Presentation follows receipt of FDA Fast Track designation for BH-30643 for the treatment of advanced or metastatic EGFR C797S-positive NSCLC

SAN DIEGO, Sept. 15, 2026 (GLOBE NEWSWIRE) — BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced updated data from the ongoing Phase 1/2 SOLARA trial of BH-30643 in non-small cell lung cancer (NSCLC) patients with secondary epidermal growth factor receptor (EGFR) resistance mutations such as EGFR C797S. The data were highlighted in a mini-oral presentation at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer in Seoul, South Korea.

BH-30643 is an investigational, novel, orally bioavailable, non-covalent, macrocyclic, brain active, mutant-selective, OMNI-EGFR™ inhibitor designed to overcome the limitations of currently approved EGFR inhibitors for the treatment of EGFR-mutant NSCLC. In patients with EGFR C797S-positive resistance to prior EGFR inhibitor treatment, with or without concurrent T790M, BH-30643 demonstrated a 45% objective response rate (ORR; 18/40) and an 88% disease control rate (DCR; 35/40). At the time of efficacy follow-up, 63% (25/40) of patients remained on treatment with a median follow-up of 6.9 months. BH-30643 also demonstrated a favorable safety profile with low rates of dose reduction or discontinuation due to treatment-related adverse events.

“C797S-driven resistance to third-generation EGFR inhibitors was first described over 10 years ago, yet patients whose tumors develop this mutation currently have no approved targeted treatment options,” said Hidehito Horinouchi, M.D., Ph.D., National Cancer Center Hospital, Tokyo, and presenting author of the study. “The responses observed with BH-30643 in this heavily pretreated population, together with encouraging early evidence of durability, support the potential of BH-30643 to directly target this resistance mechanism. These results are particularly encouraging given the need for new precision treatment options that can extend the benefits of targeted therapy for patients with EGFR-mutant lung cancer.”

“These updated results provide important clinical validation of the approach we took in intentionally designing BH-30643 to address on-target EGFR resistance, including C797S,” said Geoff Oxnard, M.D., Chief Medical Officer of BlossomHill Therapeutics. “We are encouraged to see meaningful anti-tumor activity across a molecularly diverse group of patients with C797S-positive disease, including patients with concurrent T790M and those who have received multiple prior therapies, with a favorable safety profile. Together with the recent FDA Fast Track designation, these data strengthen our conviction in the potential of BH-30643 and support our plans to advance into a Phase 2 trial in patients with C797S-positive NSCLC in 2027.”

Presentation highlights:

As of the May 12, 2026 data cutoff, with efficacy follow-up through August 10, 2026:

  • Encouraging anti-tumor activity was observed in patients with C797S-positive resistance. Among 40 patients with EGFR C797S-positive resistance to prior EGFR inhibitor treatment, with or without concurrent T790M, 18 patients achieved a confirmed (16) or ongoing unconfirmed (2) partial response, representing an ORR of 45% (95% CI: 29%-62%). The DCR was 88% (35/40), and 25 patients (63%) remained on treatment at the time of efficacy follow-up. Median follow-up was 6.9 months.
  • Activity was observed across a clinically heterogeneous, previously treated population. Patients had received a median of two prior lines of therapy; 98% had received prior osimertinib, 53% had received prior chemotherapy and/or an antibody-drug conjugate, and 53% had a history of brain metastases. 35% of patients had concurrent T790M.
  • BH-30643 demonstrated a favorable safety profile at expansion doses. Among 174 patients treated at doses of 40 mg, 50 mg and 60 mg twice daily, treatment-related dose reductions and discontinuations occurred in 9% and 3% of patients, respectively. EGFR wild-type-associated treatment-related adverse events were primarily Grade 1. The most common treatment-related adverse event was bilirubin elevation, which was generally asymptomatic and predominantly unconjugated, consistent with UGT1A1 inhibition by BH-30643.
  • Development of BH-30643 is continuing across multiple EGFR-mutant populations. Expansion cohorts are evaluating on-target resistance mutations, targeted therapy-naive patients and BH-30643 in combination with chemotherapy. BlossomHill plans to initiate a global Phase 2 study targeting EGFR C797S-positive NSCLC in Q1 2027.

The presentation is available on the company’s Posters & Presentations page here: https://bhtherapeutics.com/pipeline/#posters-and-presentations.

About BH-30643
BH-30643 is an investigational, novel, orally bioavailable, non-covalent, macrocyclic, brain active, mutant-selective, OMNI-EGFR™ inhibitor for the treatment of EGFR-mutant NSCLC. BH-30643 was designed to overcome the limitations of currently approved EGFR inhibitors, which were discovered over a decade ago without the current, modern understanding of the structure and protein dynamics of mutant EGFRs. In preclinical studies, BH-30643 demonstrated potent inhibitory activity across diverse EGFR mutation categories – classical mutations, on-target resistance mutations such as C797S with or without T790M, atypical mutations and exon 20 insertions – while maintaining marked selectivity over wild-type EGFR. BH-30643 has received Fast Track designation and is being evaluated in SOLARA, a global Phase 1/2, first-in-human clinical trial spanning more than 40 sites in 10 countries. Ongoing dose expansion cohorts are enrolling in both TKI-pretreated and TKI-naive settings, including a C797S resistance cohort. For additional information on SOLARA, including a list of study sites and how to enroll, please visit clinicaltrials.gov (NCT06706076).

About the SOLARA Trial
The Phase 1/2 SOLARA clinical trial (NCT06706076) is a global, open label, multicenter study assessing the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of BH-30643 in patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). Phase 1 will determine the recommended Phase 2 dose (RP2D) of BH-30643 as a monotherapy and in combination with chemotherapy. Phase 2 is designed to evaluate the antitumor efficacy and safety in specified cohorts determined by mutation subtypes and/or treatment history at the RP2D, as well as the population pharmacokinetics.

About BlossomHill Therapeutics
BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment. Founded and led by industry veteran J. Jean Cui, Ph.D., with her proven track record in oncology drug design and development – including three FDA-approved drugs – BlossomHill Therapeutics applies cutting-edge science with a goal to address key oncogenic drivers and improve patient outcomes in difficult-to-treat cancers. The company’s lead clinical program is BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFRTM inhibitor for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), which has received Fast Track designation for the C797S resistance population after 3rd generation EGFR TKI treatment. The company is also conducting clinical development of BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor initially being studied in a clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS). The company’s pipeline also includes BH-501284, a preclinical, non-covalent, selective, pan-KRAS Switch-II inhibitor for potential future development in diverse KRAS-mutant tumors.

BlossomHill Therapeutics is headquartered in San Diego, California. For more information, visit bhtherapeutics.com and follow us on LinkedIn and X.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws, including, without limitation, statements regarding: the therapeutic potential, clinical benefits, safety and potential competitive differentiation of the company’s product candidates, including BH-30643, BH-30236 and BH-501284; the anticipated benefits of regulatory designations received, or that may be received, by the company’s product candidates; the design, enrollment, timing, progress and results of the company’s clinical trials and preclinical studies; the company’s planned regulatory interactions and submissions; anticipated program milestones, announcements and updates, including the initiation of the Phase 2 study for BH-30643 in Q1 2027; statements by the company’s management; and the company’s development plans and continued advancement of its pipeline. The words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “upcoming,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially, including, without limitation: the company’s limited operating history, history of significant losses and the early stage of development of its product candidates; the risk that preliminary and interim clinical data are subject to further analysis and may not be predictive of, may be inconsistent with, or may be more favorable than, data generated as clinical trials continue or data from future clinical trials; uncertainties inherent in the initiation, timing, design and enrollment of clinical trials, and the availability and timing of data from ongoing and future trials; the company’s ability to successfully demonstrate the safety and efficacy of its product candidates and to obtain and maintain regulatory approvals; the timing and outcome of planned interactions with, and submissions to, the FDA and other regulatory authorities, including whether an accelerated approval pathway will be available to the company; the risk that regulatory designations, including Fast Track and orphan drug designation, may not result in a faster development, review or approval process, do not increase the likelihood of regulatory approval, and may be withdrawn; competition from third parties that are developing products for similar indications; the prior success of the company’s management team not being indicative of future success; the company’s reliance on third parties, including contract research organizations and contract manufacturing organizations; the company’s ability to obtain, maintain and protect its intellectual property; and the company’s need for additional financing and its estimates regarding operating expenses and capital requirements. These and other risks are described in greater detail under the heading “Risk Factors” in the company’s final prospectus filed with the Securities and Exchange Commission (the “SEC”) on August 7, 2026 pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, as well as in the company’s subsequent filings with the SEC. Any forward-looking statements represent the company’s views only as of the date of this press release, and the company expressly disclaims any obligation to update any forward-looking statements, except as required by law.

Company Contact:
Michael Moore, BlossomHill Therapeutics
michael.moore@bhtherapeutics.com

Media:
Ashlea Kosikowski, 1AB
ashlea@1abmedia.com

Partnership to Support Development and Qualification Efforts for Photonics Products

GOLETA, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) — Aeluma, Inc. (NASDAQ: ALMU), a semiconductor company specializing in high-performance, scalable technologies for AI, mobile and consumer, defense and aerospace, and quantum, announced today it has executed an agreement with Sumitomo Chemical Advanced Technologies (SCAT) to accelerate development and production of photonics wafers for the AI datacom market. The agreement will initially leverage existing metalorganic chemical vapor deposition (MOCVD) capabilities at SCAT’s Phoenix, Arizona manufacturing facility, and provides a path for increasing capacity in the future.

Aeluma’s large-diameter non-indium-phosphide (non-InP) photonics platform combines best-in-class materials with mass-market microelectronics manufacturing. With InP substrates in short supply, and geopolitics adding risk and uncertainty, alternative approaches are being considered to meet the demand for high-performance photonics components such as photodetectors and lasers. Traditional InP manufacturing is carried out on 100mm substrates and smaller. While 150mm InP lines are being established, new fabs require time and resources to qualify, and InP substrates are expensive and in short supply.

Aeluma’s heterogeneous integration approaches leverage non-InP substrates such as 150mm gallium arsenide (GaAs) and 200 to 300mm silicon (Si) that are more readily available. In addition to the partnership with SCAT, Aeluma complements its in-house MOCVD capabilities by working with established large-volume GaAs and Si foundries for component fabrication, eliminating dependence on new fab buildouts and associated qualification timelines.

SCAT, a solely owned subsidiary of Sumitomo Chemical, produces epitaxial wafers at its facility in Phoenix, Arizona for the optical communications, smartphone, wireless, and automotive industries.

“SCAT is an ideal partner to pair with Aeluma’s in-house MOCVD that is capable of producing wafers of any size, including large-diameter 150, 200, and 300mm substrates,” said Jonathan Klamkin, Ph.D., Founder and CEO of Aeluma. “We have been working with SCAT for several years. This new agreement aims to strengthen our relationship and set the stage for accelerated development, qualification, production, and future potential expansion.”

“We look forward to continued partnership with Aeluma,” added Dr. Ken Campman, President & Executive Officer from SCAT. “The demand for epitaxial wafers for photodetectors and lasers has grown significantly, but InP substrate supply is limiting development and production efforts. Aeluma’s technology is a promising solution for the datacom market and may impact other markets as well.”

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

About Aeluma

Aeluma (NASDAQ: ALMU) is a transformative semiconductor company specializing in high-performance photonic and electronic technologies that scale. The company’s proprietary platform combines compound semiconductors with scalable manufacturing used for mass market microelectronics to enable volume production and large-scale integration. Applications for Aeluma’s technology include mobile, AI, defense and aerospace, robotics, automotive, AR/VR, and quantum. Headquartered in Goleta, California, Aeluma operates state-of-the-art R&D and manufacturing capabilities for semiconductor wafer production, quick-turn chip fabrication, rapid prototyping, test and validation. Aeluma also partners with production-scale fabrication foundries, packaging, and integration companies. For more information, visit www.aeluma.com.

Company:
Aeluma, Inc.
(805) 351-2707
info@aeluma.com

Investor Contact:
Financial Profiles, Inc.
Moira Conlon and Donni Case
(310) 622-8224
ir@aeluma.com

VANCOUVER, British Columbia, Sept. 15, 2026 (GLOBE NEWSWIRE) — Yukon Metals Corp. (CSE: YMC, FSE: E770, OTCQB: YMMCF) (“Yukon Metals” or the “Company”) is pleased to report that a recently completed induced polarization (“IP”) geophysical survey at its 100%-owned Birch Project (“Birch” or the “Project”) has identified a new target zone approximately 2 kilometres south of known skarn mineralization.

Highlights

  • Multiple chargeability anomalies identified south of the Birch skarn expand the exploration footprint into a broader intrusive system.
  • The anomalies coincide with a mapped intrusive body and magnetic high and elevated molybdenum-in-soil geochemistry.
  • Select grab samples in the same area returned grades up to 16 grams per tonne (“g/t”) gold, 1,825 g/t silver, and 0.43% copper (News Release Dec 8, 20251).
  • One of the new IP targets was tested by diamond drilling during the 2026 program, with assays pending.

“The IP survey identified a large chargeability anomaly approximately two kilometres south of the skarn zone we had identified and drilled in 2025, and it is present on every principal line we have surveyed,” says Jim Coates, CEO of Yukon Metals. “The anomaly sits directly beneath the area where geochemistry, geology and magnetics had already directed our attention, and it was tested by drilling hole 12 this season. The IP data alongside completed surface geochemistry, geology and magnetic response provide multiple independent methods that help guide our efforts towards a potential system. We look forward to reporting additional data as we continue to evaluate and explore the Birch district.”

Southern Birch Target and IP Survey Results

Exploration at Birch initially focused on the near-surface skarn mineralization, which provided clear and accessible drill targets. As work progressed, geological mapping, geochemistry and geophysics have increasingly pointed to a broader intrusive-related mineralizing system extending beyond the known skarn.

Skarn mineralization commonly develops where hydrothermal fluids associated with intrusive systems react with favourable host rocks, particularly carbonate-rich units such as limestone and marble. As a result, skarn occurrences can provide an important vector toward the intrusive source of a mineralizing system, including porphyry-style or other intrusion-related systems. At Birch, the relationship between the known skarn mineralization and the broader intrusive footprint is therefore an important part of the evolving exploration model.

Approximately 2 kilometres south of the drilled skarn area, previous exploration identified a coincident combination of elevated molybdenum-in-soil geochemistry, anomalous gold-silver-copper surface samples, mapped intrusive rock and a magnetic high corresponding with a low potassium/thorium ratio zone in the radiometric data. Select rock samples collected in 2025 (News Release Dec 8, 2025) returned values of up to 16 g/t gold, 1,825 g/t silver and 0.43% copper from this broader southern target area.

The 2026 IP survey was designed to add subsurface information to this developing exploration model and to test for chargeable features beneath the intrusive target. A total of 12.7 line-kilometres of 2D IP surveying was completed at Birch across four principal north-south survey lines and an east-west tie line. The principal lines were spaced approximately 300 metres apart.

Induced polarization and electrical resistivity are measured together in the same survey by passing an electrical current through the ground and recording how the rock responds. Resistivity reflects how readily current flows through the rock, and can distinguish between rock types, alteration and structures; chargeability – the IP response – measures how briefly the ground holds an electrical charge after the current is switched off, a property that is generally elevated where disseminated sulphide minerals are present.

Granodiorite intrusions and marble/limestone act like electrical insulators that resist current flow and show up as high-resistivity bodies, while schist is lower resistivity. The sulfide-bearing zones, such as skarn with pyrrhotite and chalcopyrite, and porphyry potassic zones hold an electrical charge that creates chargeability anomalies. Because sulphides are commonly associated with the metals of interest in porphyry and skarn systems, chargeability anomalies are used to identify prospective zones for drilling.

3D oblique view of IP survey looking southwest, showing the northern IP anomaly as warm colors closest to the reader.
Figure 1: 3D oblique view of IP survey looking southwest, showing the northern IP anomaly as warm colors closest to the reader.

Birch Project compilation map showing the known skarn mineralization and the southern Birch target, with drilling, surface sampling, molybdenum-in-soil geochemistry, geology, and 2026 IP survey coverage.
Figure 2: Birch Project compilation map showing the known skarn mineralization and the southern Birch target, with drilling, surface sampling, molybdenum-in-soil geochemistry, geology, and 2026 IP survey coverage.

The 2D inversion sections identified chargeability responses across the survey grid. At the north end of the grid a chargeability anomaly is observed across multiple survey lines (Figure 2); this target was tested by one drill hole during the 2026 program, with results pending. In the southern portion of the grid, a separate chargeability anomaly is present to varying degrees on all four principal survey lines at approximately 400 metres below surface. An increased chargeability response is also observed on the east-west tie line, although at lower amplitude than on the principal lines.
Birch Project 2D chargeability inversion sections for IP Lines 1–4. Arrows highlight the northern chargeability anomaly across the four principal survey lines; a separate chargeability response is also observed in the southern portion of the grid.
Figure 3: Birch Project 2D chargeability inversion sections for IP Lines 1–4. Arrows highlight the northern chargeability anomaly across the four principal survey lines; a separate chargeability response is also observed in the southern portion of the grid.

The IP interpretation also notes that strong chargeability responses occur locally along the edge of resistive features. Aurora Geosciences Ltd. (“Aurora Geosciences”), which completed the Company’s Birch IP survey, noted that this relationship may warrant further investigation in a skarn-style geological setting where mineralization is commonly developed at the contact between intrusive rocks and reactive host rocks (Figure 3).

Together, the surface geochemistry, geology, magnetic response and new IP data provide multiple independent datasets for evaluating the broader mineralizing system south of the known skarn. One of the identified IP targets was tested during the 2026 drill program, with results pending (Figure 1).

Birch Project 2D chargeability and resistivity inversion sections for IP Line 1, illustrating the spatial relationship between the southern chargeability response and adjacent resistive features.
Figure 4: Birch Project 2D chargeability and resistivity inversion sections for IP Line 1, illustrating the spatial relationship between the southern chargeability response and adjacent resistive features.

IP Survey Methodology

The Birch IP survey was completed by Aurora Geosciences in June 2026. The survey comprised 12.7 line-kilometres using an in-line proximal pole-dipole configuration. Four north-south principal lines were completed at approximately 300-metre spacing, together with an east-west tie line. Nominal dipole spacing was 100 metres, with nominal current injection spacing of 50 metres.

The survey utilized IRIS V-Fullwaver receivers and a GDD TX IV 5.0 kW IP transmitter. Data was collected in the time domain using a 0.125 Hz reversing-polarity waveform and 20 chargeability windows following a 40-millisecond delay.

The survey configuration was designed to provide investigation depths of up to approximately 1,200 metres on the principal lines and 750 metres on the tie line, although effective investigation depth varies depending on subsurface electrical properties and data quality. Data quality at Birch was generally good. Of approximately 3,300 measurements, about 3% of resistivity readings and 7% of chargeability readings were removed during quality-control processing due to poor decay curves, elevated error values or unreasonable results. Line 3 contained a higher proportion of rejected chargeability measurements than the other lines and has been interpreted with consideration of observations from neighbouring lines and the tie line.

Next Steps

Yukon Metals is continuing to integrate the Birch IP results with geological mapping, soil and rock geochemistry, magnetic data and drilling. Follow-up mapping and prospecting in August 2026 refined the southern intrusive contact and identified molybdenite and local copper-bearing mineralization within the granodiorite, with alteration and veining increasing slightly along its northern contact. Garnet-pyroxene skarn boulders were also identified near the intrusive contact, supporting continued evaluation of the area for skarn-style mineralization. Pending assay and hyperspectral results from this work will be incorporated with the geophysical data to refine priority areas for further mapping, sampling, IP and future drill targeting.

About the Birch Project

Birch is a 7,000-hectare copper-gold exploration property located in western Yukon, approximately 65 kilometres northeast of Burwash Landing. The 100%-owned, helicopter-accessed property represents an emerging copper-gold exploration opportunity within Yukon Metals’ broader Yukon portfolio, with multiple target areas identified across the Project. Exploration to date has outlined skarn-style copper-gold mineralization, while geological, geochemical, and geophysical work suggests the potential for additional epithermal and porphyry-style mineralized systems.

Building on the 2025 program, which included 1,685 metres of HQ diamond drilling in 6 holes and established a broad copper-gold skarn footprint at Birch, Yukon Metals’ 2026 exploration program included approximately 2,600 metres of additional diamond drilling, 12.7 line-kilometres of IP surveying, and follow-up geological mapping and rock sampling across priority target areas.

About Yukon Metals Corp.

The Yukon Metals portfolio was built on more than 30 years of prospecting by the Berdahl family, the prospecting team behind Snowline Gold Corp.’s portfolio. The portfolio consists primarily of copper-gold projects, with substantial exposure to tungsten. Additional portfolio assets include gold, silver and lead-zinc polymetallic properties.

The Company is well financed and led by an experienced Board of Directors and management team across technical and financial disciplines. Yukon Metals is focused on fostering sustainable growth and prosperity within Yukon’s local communities, while simultaneously enhancing stakeholder value. The Company’s strategy centers around inclusivity and shared prosperity, offering both community members and investors the chance to contribute to, and benefit from, its ventures.

The Yukon

The Yukon Territory is an underexplored and minerally endowed district with a mining history dating back to the Klondike Gold Rush of 1898. With a progressive permitting regime, geopolitical stability and supportive government, it is well positioned to foster the next generation of mines. The Yukon is host to a highly experienced and conscientious local workforce, fostered by a long culture of exploration coupled with deep respect for the land. Recent major discoveries with local roots such as Snowline Gold Corp.’s Rogue Project – Valley Discovery, demonstrate the Yukon’s potential to generate fresh district-scale mining opportunities.

Qualified Person

The technical content of this news release has been reviewed and approved by Helena Kuikka, P.Geo., VP Exploration for Yukon Metals and a Qualified Person (as defined by National Instrument 43-101).

“ON BEHALF OF THE BOARD OF YUKON METALS CORP.

“Jim Coates”

Jim Coates, CEO
Email: jimcoates@yukonmetals.com

For additional information, please contact:
Lindsay Wilson
VP, Investor Relations & Communications
Email: lindsaywilson@yukonmetals.com 
Phone: 1 (778) 996-2192

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This news release contains certain forward-looking information, including information regarding the interpretation and geological significance of IP data, surface geochemistry, geology, magnetic responses and survey results at the Birch Project, the potential relationship between skarn occurrences and intrusive sources of a mineralizing system, the integration of data with geological, geochemical and drilling results, the potential to refine future exploration targets at Birch, and the Company’s future exploration plans and intentions. Wherever possible, words such as “may”, “will”, “should”, “could”, “can”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential”, or the negative or other variations of these words, or similar words or phrases, have been used to identify the forward-looking information. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof.

Forward-looking information involves significant risks, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from those discussed or implied in the forward-looking information. Such factors include, among other things: risks and uncertainties relating to Birch and other properties not being prospective copper-rich, gold-rich or silver-rich geological systems; rock samples analysed not being representative of overall mineralization; the Company’s ability to report additional data as it continues to evaluate and explore the Birch district; timing and receipt of outstanding assay and hyperspectral results from the Company’s 2026 exploration program; the required assumptions of completed surface geochemistry, geology and magnetic response surveys; the ability of chargeability anomalies to identify prospective drill zones and suggest additional epithermal and porphyry-style mineralized systems; the Yukon not having the potential to generate fresh district-scale mining opportunities; and other risks and uncertainties. See the section entitled “Risk Factors” in the Company’s listing statement dated May 30, 2024, available under the Company’s profile on SEDAR+ at www.sedarplus.ca for additional risk factors. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking information. Although the forward-looking information contained in this news release is based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with the forward-looking information. The forward-looking information is made as of the date of this news release, and the Company assumes no obligation to update or revise the information to reflect new events or circumstances, except as required by law.

_______________________
1 Grab samples are selective by nature and are not necessarily representative of the mineralization hosted on the property. Comprehensive grab samples can be found in the Company’s news release dated December 8, 2025.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/597a2632-36b7-4bb8-9a33-518908b28d99

https://www.globenewswire.com/NewsRoom/AttachmentNg/e826267c-4927-432c-8348-8f915b27778c

https://www.globenewswire.com/NewsRoom/AttachmentNg/ec59bb88-31c1-4857-b58d-a4347faa5fb5

https://www.globenewswire.com/NewsRoom/AttachmentNg/da683111-1b28-4327-bbb5-fc28370f2a74

Maiden drill program advancing at the historic Kuhn tungsten system, with drilling encountering broad skarn intervals

VANCOUVER, British Columbia, Sept. 15, 2026 (GLOBE NEWSWIRE) — GoldHaven Resources Corp. (“GoldHaven” or the “Company”) (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS) is pleased to provide an update on its ongoing maiden diamond drill program at the 100%-owned Magno Project, located in the Cassiar District of northern British Columbia.

  • Over 800 metres drilled from the first drill pad at the historic Kuhn tungsten system, with drilling continuing across multiple planned drill fences.
  • Initial drilling encountered an approximately 20-metre interval of skarn, where historical interpretation had mapped two separate narrower skarn bands.
  • Historic drilling at Kuhn returned strong tungsten intercepts, including 13.0 m grading 0.55% WO₃ and 11.3 m grading 0.59% WO₃ + 0.10% MoS₂.*
  • Historical work outlined approximately 616,500 tonnes grading 0.48% WO₃ across four modeled lenses at the Kuhn–Dead Goat system.*
  • Current drilling is targeting the geometry and continuity of the tungsten-bearing skarn, while testing potential extensions beyond historically drilled areas.

Historical results and estimates pre-date NI 43-101 and are subject to the applicable cautionary language provided in this release.

Diamond drilling commenced in late August at the historic Kuhn tungsten skarn system, with over 800 metres of drilling completed to date in four (4) drill holes from the first drill pad (Pad A). The initial phase of drilling is designed to test the geometry, continuity and potential extensions of the historically identified tungsten-bearing skarn mineralization while providing the first modern drill data.

Drilling in the first three drill holes has encountered broad intervals of skarn alteration and sulphide mineralization within the top 100m, including an approximately 20-metre interval of skarn in the second drill hole. This interval is particularly notable because the historical geological interpretation at this site was mapped as two separate skarn bands, whereas initial observations from the current drilling suggest the possibility of a broader, more continuous skarn package. The fourth drill hole (GOH26-04) has confirmed a never before explored down-dip extension of the skarn unit.

Visually, the geology encountered in the first drill holes appears to match the lithological descriptions described in the historical drill logs and reports. Further, analysis with a portable XRF indicates the presence of tungsten within the skarn intersections.

Rob Birmingham, CEO of GoldHaven, commented:

“The first phase of drilling at Magno is doing exactly what we wanted it to do – giving us a modern look at a historically important tungsten system that has seen very limited exploration for decades. We are encouraged by the scale of the skarn alteration encountered in the early holes, particularly where drilling appears to show a broader package than suggested by the historical interpretation. With drilling continuing, our priority is to systematically test Kuhn and build the geological framework needed to determine the scale and continuity of the system.”

Kuhn Drilling Update

The current drilling is focused on systematically testing the historic Kuhn tungsten system through a series of drill fences designed to provide greater geological control across the mineralized trend.

The four initial drill holes from Pad A are designed to test the system at greater depth and evaluate potential extensions. Following completion of the first pad, the drill is planned to advance to a second drill pad along strike where approximately three to four additional holes are planned.

The Company’s objective during this phase is to establish multiple modern drill sections across Kuhn, providing significantly improved information on the geometry, thickness and continuity of the skarn system and allowing direct comparison with historical drilling.

Drilling remains ongoing at Kuhn, with results from the current program being integrated with historical drilling, surface geology and modern geophysical data to guide subsequent drill targeting. Results from the current program, together with historical drilling, surface geology and modern geophysical data, will be used to determine whether additional drilling is warranted at Kuhn before the program advances to other priority targets within the Magno property.

Historic Kuhn Tungsten System

The Kuhn–Dead Goat area hosts a series of historically defined tungsten-bearing skarn lenses. Historical work outlined an estimate of approximately 616,500 tonnes grading 0.48% WO₃ across four modeled lenses.

Historical drilling at Kuhn included reported intersections of:

  • 13.0 metres grading 0.55% WO₃
  • 11.3 metres grading 0.59% WO₃ and 0.10% MoS₂
  • 4.0 metres grading 1.32% WO₃ and 0.26% MoS₂

The historical estimate and drill results pre-date NI 43-101 and should not be considered a current mineral resource or mineral reserve. A Qualified Person has not completed sufficient work to

classify the historical estimate as a current mineral resource, and GoldHaven is not treating the historical estimate as a current mineral resource.

The current program represents an important step toward establishing modern geological and analytical data across the Kuhn system and evaluating the continuity and potential extensions of the historically identified tungsten mineralization.

Kuhn Tungsten Skarn Target – Historical Cross Section and 2026 Drill Testing. Historical geological interpretation of the Kuhn tungsten-skarn system showing historical drilling and mineralized skarn lenses, together with GoldHaven’s four 2026 drill holes from Pad A.Figure 1. Kuhn Tungsten Skarn Target – Historical Cross Section and 2026 Drill Testing. Historical geological interpretation of the Kuhn tungsten-skarn system showing historical drilling and mineralized skarn lenses, together with GoldHaven’s four 2026 drill holes from Pad A.

Representative drill core from GOH26-01 at the Kuhn tungsten target, showing skarn alteration, quartz veining and sulphide mineralization. Assays are pending.

Figure 2. Representative drill core from GOH26-01 at the Kuhn tungsten target, showing skarn alteration, quartz veining and sulphide mineralization. Assays are pending.

Broader Magno Drill Program

Kuhn represents the first phase of a broader drill campaign across the district-scale 37,000+ hectare Magno Project.

Following the initial Kuhn program, GoldHaven intends to evaluate additional high-priority drill targets, including the D Zone and broader Magno target area, where historical exploration and recent surface work have identified significant silver, lead, zinc, gold and copper mineralization.

Drill targeting across Magno is being supported by the integration of historical drilling and underground workings, surface mapping and geochemistry, and GoldHaven’s recently completed 2,320.7 line-kilometre airborne magnetic and QMAGT survey. The Company continues to integrate these datasets as drilling progresses and new geological information becomes available.

The 2026 program is being completed by Northtech Drilling and represents the first modern, systematic drill campaign undertaken by GoldHaven at Magno.

Diamond drilling underway at the Kuhn tungsten target, Magno Project, northern British Columbia.

Figure 3. Diamond drilling underway at the Kuhn tungsten target, Magno Project, northern British Columbia.

Next Steps

Drilling remains ongoing at Kuhn, with the immediate program focused on completing the planned drill fences and evaluating the continuity of the skarn system. Core is being logged, sampled and submitted for laboratory analysis, with assay results to be released as they are received, reviewed and verified.

The Company will use the geological observations and analytical results from the initial Kuhn drilling to refine subsequent drill targeting both at Kuhn and across the broader Magno Project.

Qualified Person:

The technical and scientific information contained in this news release has been reviewed and approved by Raymond Wladichuk P.Geo. who is a non-independent Qualified Person as defined under NI 43-101 and a consultant of the Company.

About GoldHaven Resources Corp.

GoldHaven Resources Corp. is a Canadian junior exploration company focused on advancing highly prospective mineral projects in North and South America. The Company’s flagship asset is the district-scale Magno Project in the Cassiar District of northern British Columbia. GoldHaven also owns the Three Guardsmen copper-gold project in British Columbia and the Copeçal Gold Project in Mato Grosso, Brazil. In addition, the Company holds a portfolio of critical mineral projects in Brazil.

On Behalf of the Board of Directors

Rob Birmingham, Chief Executive Officer

For further information, please contact:
Rob Birmingham, CEO
www.GoldHavenresources.com
info@goldhavenresources.com
Office Direct: (604) 629-8254

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE- Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information

This news release contains forward-looking statements and forward-looking information (collectively, “forward looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein including, without limitation, those listed below under the heading “Forward-Looking Statements in This News Release” are forward-looking statements. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: “believes”, “will”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, “may”, “should”, “potential”, “scheduled”, or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved. In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, that there will be investor interest in future financings, market fundamentals will result in sustained precious metals demand and prices, the receipt of any necessary permits, licenses and regulatory approvals in connection with the future exploration and development of any future projects in a timely manner, the availability of financing on suitable terms for exploration and development of future projects and the Company’s ability to comply with environmental, health and safety laws.

The Company cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward-looking statements as a result of various factors, including, operating and technical difficulties in connection with mineral exploration and development activities, actual results of exploration activities, the estimation or realization of mineral reserves and mineral resources, the inability of the Company to obtain the necessary financing required to conduct its business and affairs, as currently contemplated, the inability of the Company to enter into definitive agreements in respect of possible Letters of Intent, the timing and amount of estimated future production, the costs of production, capital expenditures, the costs and timing of the development of new deposits, requirements for additional capital, future prices of precious metals, changes in general economic conditions, changes in the financial markets and in the demand and market price for commodities, lack of investor interest in future financings, accidents, labour disputes and other risks of the mining industry, delays in obtaining governmental approvals, permits or financing or in the completion of development or construction activities, changes in laws, regulations and policies affecting mining operations, title disputes, the inability of the Company to obtain any necessary permits, consents, approvals or authorizations, including by the Exchange, the timing and possible outcome of any pending litigation, environmental issues and liabilities, and risks related to joint venture operations, and other risks and uncertainties disclosed in the Company’s latest interim Management’s Discussion and Analysis and filed with certain securities commissions in Canada. All of the Company’s Canadian public disclosure filings may be accessed via www.sedarplus.ca and readers are urged to review these materials.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update any of the forward-looking statements in this news release or incorporated by reference herein, except as otherwise required by law.

Forward-Looking Statements in This News Release

The following statements in this news release constitute forward-looking information:

  • the Company’s plans to complete the planned drill fences at the Kuhn tungsten system and to advance the drill program to a second drill pad along strike, where approximately three to four additional holes are planned;
  • GoldHaven’s intention, following completion of the initial Kuhn program, to evaluate additional high-priority drill targets across the Magno Project, including the D Zone and broader Magno target area;
  • expectations regarding the timing of release of assay results from the current drill program as they are received, reviewed and verified;
  • the Company’s plans to use geological observations and analytical results from the initial Kuhn drilling to refine subsequent drill targeting both at Kuhn and across the broader Magno Project, and to determine whether additional drilling is warranted at Kuhn before the program advances to other priority targets; and
  • the potential for extensions of the tungsten-bearing skarn mineralization at Kuhn beyond the areas that have been historically drilled.

Photos accompanying this announcement are available at 

https://www.globenewswire.com/NewsRoom/AttachmentNg/3fb0527e-0f63-4453-9191-cf8119c06d27

https://www.globenewswire.com/NewsRoom/AttachmentNg/a8b215d2-4fad-444d-8790-b5a6c558c329

https://www.globenewswire.com/NewsRoom/AttachmentNg/3abd4333-49bf-4454-b5b8-e0889dbd6bce

 

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) — Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced four poster presentations at the 31st Annual Congress of the World Muscle Society (WMS). The Congress will take place in Hiroshima, Japan, from Sept. 29 to Oct. 3, 2026.

Details of the scientific posters at WMS:

Date & Time: Wednesday, Sept. 30, 5:15-6:15 p.m. JST

Poster 2.74P: BASECAMP: A Phase 2a Dose Comparison and Exploratory Efficacy Study of Forazapadin (SAT-3247) in Ambulatory Boys with Duchenne Muscular Dystrophy
Presenter: Anne M. Connolly, MD, Chief of the Division of Neurology at Nationwide Children’s Hospital

Poster 2.75P: TRAILHEAD: An Open-Label Study Evaluating Long-Term Safety and Efficacy of Forazapadin (SAT-3247) in Adults with Duchenne Muscular Dystrophy (DMD)
Presenter: Anne M. Connolly, MD, Chief of the Division of Neurology at Nationwide Children’s Hospital

Poster 2.68eP: Preclinical to human translation of regenerative index: quantification of progressive muscle degeneration and disease-modifying treatment response
Presenter: Ryan Mitchell, PhD, Satellos Senior Vice President, Head of Corporate Development

Date & Time: Wednesday, Sept. 30, 5:15-6:15 p.m. JST

Poster 3.31eP: Rationale and design of a safety, tolerability, and long-term efficacy study of Forazapadin (SAT-3247) in facioscapulohumeral muscular dystrophy (FSHD)
Presenter: Wildon Farwell, MD, Satellos Chief Medical Officer

The Satellos posters will be available in the Presentations and Publications section of the Satellos website.

ABOUT FORAZAPADIN
Forazapadin is a proprietary, oral, small molecule drug candidate being developed by Satellos as a novel approach to regenerating skeletal muscle lost in Duchenne muscular dystrophy (DMD) and other degenerative muscle diseases or injury conditions. Forazapadin targets AAK1, a key protein identified by Satellos as capable of helping restore the body’s natural muscle repair and regeneration biology, a fundamental process that is disrupted in DMD and other degenerative conditions. By inhibiting AAK1 forazapadin treatment aims to re-establish a biochemical signal needed to support muscle regeneration. Satellos is advancing forazapadin as a potential treatment for DMD that is independent of dystrophin and applicable regardless of exon mutation status as either a stand-alone or adjunctive therapy, with ongoing Phase 2 clinical studies including BASECAMP, a global, randomized, placebo-controlled study in pediatric participants, and TRAILHEAD, an open-label study in adult participants.

The Company previously referred to the program as SAT-3247 and expects to transition to broader use of the INN in future scientific, regulatory and corporate communications

ABOUT SATELLOS BIOSCIENCE INC.
Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed forazapadin, an orally administered small molecule AAK1 inhibitor designed to address deficits in muscle repair and regeneration. Forazapadin is being evaluated as a potential disease-modifying treatment, initially for Duchenne muscular dystrophy (DMD), in two Phase 2 clinical trials: BASECAMP in pediatric participants with DMD and TRAILHEAD in adults living with DMD. Satellos plans to submit an Investigational New Drug application and begin clinical research to investigate the use of forazapadin in individuals living with facioscapulohumeral muscular dystrophy (FSHD) in the second half of 2026 and has identified additional muscle diseases and injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and plans to pursue these opportunities in future clinical development. For more information, visit www.satellos.com and connect with Satellos on X, LinkedIn, Facebook and Instagram.

NOTICE ON FORWARD-LOOKING STATEMENTS
This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the possibility of pursuing regulatory approval for SAT-3247, the potential for SAT-3247 to represent a disease modifying approach to the therapeutic treatment of people living with DMD; anticipated benefits to patients from a small molecule treatment for DMD; the enrollment in, advancement and timing of results of SAT-3247 through clinical trials, including the BASECAMP and TRAILHEAD clinical trials; the pharmacodynamic properties and mechanism-of-action of SAT-3247; the potential of our approach in other degenerative muscle diseases and Satellos’ plans to pursue additional muscle diseases and injury conditions in future clinical development; SAT-3247’s prospective impact on DMD patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally, including whether results observed in the TRAILHEAD study will continue to mature or will translate to the pediatric population studied in BASECAMP; the anticipated timing for an Investigational New Drug submission to the U.S. Food and Drug Administration for SAT-3247 for evaluation in facioscapulohumeral muscular dystrophy and the anticipated timing for the launch of a related Phase 2 clinical trial; Satellos’ technologies and drug development plans; and the company’s expectations regarding the sufficiency of its cash, cash equivalents and short-term investments to fund operations, including its expectation that its current cash resources will provide a runway through 2027. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are “forward-looking information or statements.” Often, but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “believe”, “plan”, “expect”, “intend”, “estimate”, “anticipate”, “potential”, “prospective”, “assert” or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. These statements are based on assumptions and subject to risks and uncertainties. In making forward looking statements, the Company has relied on various assumptions, including but not limited to: its ability to obtain future funding on favorable terms, if at all; obtaining positive results in its clinical trials, its ability to obtain necessary regulatory approvals; its ability to arrange for the manufacturing of its product candidates and technologies; and general business, market and economic conditions. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management’s ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks and uncertainties described in more detail in the “Risk Factors” section of Satellos’ Annual Information Form dated March 27, 2026, and amended and restated short form base shelf prospectus dated August 11, 2026 (each of which is located on Satellos’ SEDAR+ profile) and incorporated by reference in Satellos’ Form F-10 filed with the Securities and Exchange Commission on August 11, 2026, and in Satellos’ public filings on EDGAR (sec.gov) and SEDAR+ (sedarplus.ca). Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise.

CONTACTS
Investors: Caitlin Lowie, Vice President, Investor Relations & Communications, ir@satellos.com
Media: Emily Williams, Senior Director, Communications, media@satellos.com

Highlights:

  • Two drill rigs mobilized for the inaugural drilling campaign at the newly discovered Nguni Prospect, a high-grade gold-in-soil anomaly with a strike length in excess of 6km.
  • One diamond drill rig will focus on the highest-grade portions of the soil anomaly with an initial drill plan comprising 18 holes for 3,500m.
  • A second reverse circulation drill rig will focus on testing the strike extension of the soil anomaly with 13 holes planned for 1,500m.
  • A step-out diamond drill program comprising 5 holes for 1,000m has been finalised to test the eastern extension of the Manga Gold Prospect, a promising gold-in-soil and gold-in-bedrock anomaly located 17km west of Nguni.

VANCOUVER, British Columbia, Sept. 15, 2026 (GLOBE NEWSWIRE) — Ongwe Minerals Inc. (TSXV: OGW) (NSX:ONG) (“Ongwe” or “the Company”) is pleased to announce the commencement of drilling at its newly discovered Nguni gold prospect, situated 17 km east of the Manga Gold discovery, at the Omatjete Gold Project.

Nguni is a large, high-grade, gold-in-soil anomaly discovered by Ongwe in May 2026 during a regional soil sampling program. The sampling program targeted the regionally significant Okondeka Fault Zone (OFZ), which hosts both WIA Gold’s Kokoseb Gold Deposit and Ongwe’s Manga Gold Discovery – see Figure 1. Situated 55 km east of Kokoseb and 17 km east of Manga, Nguni is being rapidly advanced through detailed surface work and drilling, with the aim of converting the target into a large-scale economic discovery.

Dave Underwood, Ongwe’s CEO commented: “The central portion of the Nguni gold anomaly has now been closely defined by infill soil sampling, with 50 soil samples above 300ppb Au, peaking at 1,310ppb Au. This represents a 6km long, high-grade soil anomaly similar in scale and tenor to the anomaly at the neighbouring Kokoseb gold deposit, before it was drilled. We are now embarking on the maiden, fully funded drill program at this exciting target. A diamond drill rig has been mobilized to test the highest-grade portion of the anomaly so that we can collect detailed geological, structural and mineralogical information upfront, in order to better guide the follow-on drill program. The lower grade (central) portions of the anomaly will be scout drilled using an RC rig, which provides a quick and relatively cheap method of establishing grade potential and allows for ranking of targets.

We are also planning a diamond step-out drill program at Manga over the highest grade and width portion of the bedrock anomaly defined earlier in the year. The priority bedrock anomaly starts east of the previous RC drilling at Manga, stretches for at least a 1000m and is still open to the east”.

Map illustrating the Nguni Gold Anomaly in relation to the Manga Gold Discovery and the initial soil sampling results at the Kokoseb Gold Deposit

Figure 1: Regional map illustrating the Nguni Gold Anomaly in relation to the Manga Gold Discovery and the initial soil sampling results at the Kokoseb Gold Deposit (54.2Mt at 1.04 g/t Indicated, 35Mt at 0.99 g/t Inferred, released 16 July 2026, ASX, WIA Gold). The image highlights the primary structural control of the Okondeka Fault Zone and the scale of initial gold-in-soil results across the three discoveries.

Nguni Prospect

The Nguni gold anomaly was discovered by Ongwe during regional soil sampling along the Okondeka Fault System in May 2026. The initial regional sampling was carried out on a 200 x 200m square grid and later infilled to 50 x 50m spacing over the anomalous areas. The Nguni area is flat lying and there is very little outcrop visible. The gold anomaly lies along narrow zones of metasediments between late to post orogenic granites and appears to be in-situ within residual soils.

The Nguni anomaly extends over 6 km of strike and includes targets with varying orientations, width and intensity. A two-pronged drill program has been planned as follows:

  • A diamond drill program of approximately 18 holes for 3,500m initially, starting in the northwest corner of the anomaly and covering the higher-grade soils in the northwestern and southeastern portions.
  • A scout drill program of approximately 1,500m using an RC rig. This program is aimed at first pass testing of the lower priority targets to establish economic potential and priority.
  • Either or both programs will be expanded or modified as indicated by the logging and assay results.

Geological mapping of the limited outcrop indicates that the targeted metasedimentary units predominantly dip toward the south-southeast and the initial holes will therefore be drilled toward the north, except for one RC line positioned on the nose of the fold closure. Detailed logging of the initial core will be used to refine the drill parameters. See Figure 2.

Heat Map showing Nguni soil sample results with the planned DD and RC drill collars plotted.

Figure 2: Heat Map showing Nguni soil sample results with the planned DD and RC drill collars plotted.

RC drilling underway at the Nguni gold anomaly.

Figure 3: RC drilling underway at the Nguni gold anomaly.

Manga Prospect

The Manga prospect was discovered during the initial regional Omatjete soil sampling program carried out in Q4 2024. The 200 x 200m regional soil grid outlined an arsenic and gold anomaly approximately 4.5km long and 1km wide at the widest point. Infill sampling to 100 x 25m tightened up the surface anomaly and provided follow-up targets. The soil sampling was followed up with two trenches and eleven RC scout holes. Ten of the eleven RC holes returned anomalous gold values, several with wide low-grade intercepts including 138m @ 0.22g/t Au in hole MRC006. As the Manga area is covered by calcrete and alluvial sediment cover, a decision was taken in early 2026 to drill vertical holes through the calcrete cover and sample the top of bedrock beneath. This exploration technique was pioneered by Osino Resources at Twin Hills and has proved effective in defining mineralised footprints in hard rock below calcrete cover. The results from this program indicate that the Manga prospect becomes wider and higher grade towards the east and it is now clear that the calcrete cover gets thicker towards the east, masking the gold mineralization in the bedrock beneath.

Manga Drilling

A diamond drilling program of 5 holes for 1,000 m is planned for the Manga east extension, with an average planned depth of 200 m. The initial holes will be oriented and drilled toward the northwest, but drill parameters may be modified by the detailed logging.

The Company also plans to undertake a calcrete sampling program to trace gold mineralization beneath the calcrete cover east of the current bedrock sampling extent. If the calcrete results confirm that the mineralized trend continues, the Company will use follow-up bedrock sampling to refine the target before testing it with diamond drilling.

Heat map showing the bedrock assay results improving east of the 2024 RC drill collars.

Figure 4: Heat map showing the bedrock assay results improving east of the 2024 RC drill collars. Black triangles indicate the planned DD drill collars to be drilled in Q4 2026.

Assay Method

During the soil sampling programs, the Company initially utilized the detectORE™ analytical technique, designed to enable the measurement of trace gold concentrations in geological samples using a portable X-Ray Fluorescence (pXRF) instrument. This process overcomes the traditional limitations of gold analysis by pXRF including low gold concentrations and metal peak interference. The method involves leaching 250g of sieved material in a sealed pouch with 500ml of GLIX-20™ lixiviant and a Collector Device (CD). Following a 16-hour tumble in a Maxi Mixer barrel to dissolve the gold, the CD is removed, rinsed, and analyzed for 150 seconds using detectORE™ mode firmware. This partial analysis technique is managed through pLIMS™ software with strict QA/QC protocols to identify relative gold anomalism. An extensive orientation program was carried out before putting the detectORE™ methodology into production by comparing soil, calcrete and rock chip sample assays with Aqua Regia and FireICP. The detectORE™ system performed extremely well and identified the same anomalies as the laboratory techniques in all conditions. The detectORE™ gold technique is designed for rapid on-site assessment and is not used for the formal quantification of gold content or the estimation of Mineral Resources.

As part of the current exploration program, all soil samples undergo initial multi-element analysis utilizing the Company’s in-house pXRF. All trace element anomalies, including base metal and arsenic anomalies are then analyzed through the Company’s detectORE™ system. Any area returning a value equal to or greater than 10 detectable Units (dU) are prioritized for follow-up soil sampling. All follow-up soil samples are analyzed via Fire Assay at the MSALAB facility in Omaruru, Namibia. The fire assay procedure starts by drying the <212u and +-250g soil sample. The sample is then pulverized to 85% passing 75 microns, from which a final 50g aliquot is taken for fire assay with an Atomic Absorption (AA) finish.

QA/QC

All of Ongwe’s sample assay results have been independently monitored through a quality assurance and quality control (“QA/QC”) program including the insertion of blind standards, blanks, and field duplicate samples. The Company maintains rigorous monitoring for both in-house and laboratory analyses to ensure data reliability. For the detectORE™ process, which provides rapid on-site assessment of gold anomalism, a Certified Reference Material (CRM) sample is inserted every 15 samples to monitor the performance of the pXRF instrument and the leaching efficiency. For the formal fire assay verification conducted at MSALABS, a CRM is inserted every 30 samples. This laboratory procedure involves precise pulverization and a 50g fire assay with an Atomic Absorption (AA) finish to provide formal quantification for prioritized bedrock samples.

Data Verification

Carl Joone, BSc. (Hons), the President and Co-Founder of Ongwe Minerals Inc., and a Qualified Person for the purposes of National Instrument 43-101, has verified all the data disclosed, including a review of the sampling procedures, chain of custody, and assay results underlying the disclosure, by plotting and verifying against raw data received. Mr. Joone noted no errors or omissions during the data verification process.

Qualified Person

Carl Joone, BSc. (Hons) is the President and Co-Founder of Ongwe Minerals Inc. and is a registered Professional Natural Scientist with the South African Council for Natural Scientific Professions (Pr. Sci. Nat. No. 172695) and a Qualified Person for the purposes of National Instrument 43-101. Mr. Joone has reviewed and approved the scientific and technical information in this news release.

About Ongwe Minerals Inc.

Ongwe Minerals Inc. is a Canadian listed gold exploration company focused on the discovery and advancement of new gold systems in Namibia. The Ongwe team, previously with Osino Resources (sold to Shanjin International), has a history of making and advancing gold discoveries in Namibia, including Osino’s Twin Hills (currently in construction) and Eureka deposits, and the advancement and sale of Auryx Gold’s Otjikoto gold deposit (in production, sold to B2Gold).

The Company’s current focus is on three promising gold projects in the emerging Northwest Damara gold belt in Namibia, with a focus on the Omatjete and Khorixas Gold Projects.

The Omatjete Gold Project is strategically located along the regional Okondeka Fault Zone, which also hosts the Kokoseb gold deposit (WIA Gold). Early surface work by Ongwe led to the discovery of the Manga Gold Prospect which has a 4.5km x 1km footprint of gold in soil and early scout drilling indicating gold in bedrock. Recent regional sampling in 2026 has led to the discovery of the large scale, high tenor Nguni anomaly 17km east of Manga. Nguni currently has a strike length of 6km and is open to the west, north and east. The Omatjete Project still has significant growth potential and work is ongoing to define further anomalies along the Okondeka Fault system.

The Khorixas Gold Project is situated just 60km west of Osino’s Eureka gold project, adjacent to the northern margin of the Damara Orogenic Belt. Khorixas hosts two large-scale surface discoveries called Belmont and K17. The Belmont prospect has a surface gold footprint of approximately 12 × 6km and lies between the regional scale, basin margin, Khorixas Fault and the Belmont Thrust Zone. Calcrete and grab sampling to date have indicated eighteen target areas.

ON BEHALF OF THE BOARD OF DIRECTORS
“Dave Underwood”
Chief Executive Officer

CONTACT INFORMATION
Ongwe Minerals Inc.
Dave Underwood, Chief Executive Officer
Email: dave@ongweminerals.com
Ongwe Minerals Inc.
Carl Joone, President & Co-Founder
Email: carl@ongweminerals.com


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Cautionary Statements Regarding Forward Looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the use of proceeds from the Company’s future plans or prospects of the Company, including prospects for discovery of mineral resources or the results of future exploration programs. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking statements are necessarily based upon a number of assumptions that, while considered reasonable by management, are inherently subject to business, market and economic risks, uncertainties and contingencies that may cause actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Other factors which could materially affect such forward-looking information are described in the risk factors in the Company’s most recent annual management’s discussion and analysis which is available on the Company’s profile on SEDAR+ at www.sedarplus.ca. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

Photos accompanying this announcement are available at 

https://www.globenewswire.com/NewsRoom/AttachmentNg/5d720019-9e19-4bd3-ae78-44f04ee73de8

https://www.globenewswire.com/NewsRoom/AttachmentNg/b790238b-3b4e-42d3-bfca-2c1cb71bf0e1

https://www.globenewswire.com/NewsRoom/AttachmentNg/0c1d1e05-8c32-41c0-9131-3ad41ee69e0e

https://www.globenewswire.com/NewsRoom/AttachmentNg/1a58afc3-1d07-40e2-9829-862e7223d1f1

Limited-Edition Release Continues Distillery’s Celebration of the Art of Blending Through Whiskey, Visual Art and Community

BRECKENRIDGE, Colo., Sept. 15, 2026 (GLOBE NEWSWIRE) — Breckenridge Distillery, one of the most-awarded craft distilleries in the U.S. and part of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), is turning whiskey into a canvas with the sixth edition of its acclaimed Collectors Art Series. This year’s limited-edition release pairs Breckenridge’s award-winning whiskey-making with the bold, colorful vision of Colorado muralist, professional snowboarder and creative Pat Milbery, whose original label design celebrates the mountain spirit, community and craftsmanship that define Breckenridge.

For this year’s collaboration, the creative partnership comes to life with a new mural by Milbery at Tony P’s Bar & Pizzeria, located at 3000 Zuni St, Denver, CO 80211. The mural brings his signature style and the spirit of the Collectors Art Series into the local community, further reflecting the Distillery’s commitment to supporting artists and creative spaces. Each collaboration transforms a limited-edition whiskey release into a collectible work of art while supporting the creative community through charitable giving.

For Milbery, the collaboration is deeply personal. After moving to Breckenridge to pursue professional snowboarding, the mountain town became the backdrop for many of life’s defining moments, from launching his snowboarding career to discovering his artistic voice. Today, his signature murals can be found across four continents, where bold geometric forms, vibrant color palettes and nature-inspired imagery encourage connection, optimism and open-hearted living.

Inspired by the landscapes, friendships and unforgettable moments that shaped his journey, Milbery’s artwork captures the joyful spirit of Breckenridge through colorful mountain vistas, evergreen forests, radiant sunsets and symbolic elements that honor both community and loved ones who continue to inspire his work. The design also reflects the craft behind whiskey, drawing a parallel between the thoughtful blending of barrels, flavors and character that goes into each expression and Milbery’s own process of bringing together color, movement, memories and emotion to create a singular work of art.

“Everything about Breckenridge inspired the artwork. The friendships. The sunsets. The powder days. The evergreen forests. The crisp mountain mornings. The incredible community,” said Milbery. “The artwork also honors important people in my life, including loved ones who are no longer physically with us but continue to inspire me every day. I wanted the design to represent joyful energy, gratitude, community and the colorful journey that Breckenridge has been in my life.”

Milbery’s artwork will appear on the Breckenridge Barbados Cask Finish Whiskey, bottled at 90 proof and 45% ABV. The limited-edition expression showcases Breckenridge Distillery’s dedication to the art and craft of whiskey, bringing together carefully selected whiskey and the influence of Barbados cask finishing to create a distinctive expression. Just as Milbery thoughtfully layers color, texture and movement to create his artwork, Breckenridge’s whiskey-making process brings together distinct elements, from spirit and barrel to time and finishing, to create a finished whiskey with its own character and story.

Since its inception, the Collectors Art Series has become one of Breckenridge Distillery’s signature annual releases, highlighting acclaimed artists while reinforcing the Distillery’s longstanding support of the arts. Previous collaborators include Miles Toland, Abby Wren and Alexandrea Pangburn, each bringing a unique perspective to the series while helping raise funds for organizations that champion artists and creative spaces.

Breckenridge Collectors Art Series releases have earned numerous accolades, including 2023 Best Blended LTD Release and 2020 Icons of Whisky’s Campaign Innovator of the Year at the World Whiskies Awards, along with Gold and Double Gold medals at the San Francisco World Spirits Competition.

Breckenridge Collectors Art Series 6 will be available beginning September 15, 2026, exclusively at Breckenridge Distillery and the Main Street Tasting Room in Breckenridge, Colorado, for $125.

For more information about Breckenridge Distillery, visit breckenridgedistillery.com. Follow Breckenridge on Instagram @breckdistillery and become a fan at facebook.com/BreckDistillery. Age 21+. Always enjoy responsibly.

To learn more about Pat Milbery and view his work, visit Heart Space Studios at heartspacestudios.art, patmilbery.com and Sognar Creative Division at sognarcreativedivision.com, and follow @patmilbery on Instagram.

About Tilray Brands

Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.

About Breckenridge Distillery

Founded in Colorado in 2008, Breckenridge Distillery is the “World’s Highest Distillery,” and is best known for its award-winning blended bourbon whiskey, a high-rye mash American-style whiskey.

One of the most highly awarded distilleries in the U.S., the Breckenridge Distillery is proudly a 3x Icons of Whisky and 10x winner of Best American Blended winner at the World Whiskies Awards by Whisky Magazine and a 4x winner of Colorado Distillery of the Year by the New York International Spirits Competition. Most recently, Breckenridge Port Cask Finish was named World’s Best Finished Bourbon at the 2024 World Whiskies Awards, joining Breckenridge High Proof, named World’s Best Blended Whiskey and Breckenridge Gin, named World’s Best Compound Gin at the World Gin Awards by Gin Magazine. Breckenridge spirits have been awarded 6 Double Golds at the San Francisco World Spirits Competition.

The Breckenridge Distillery is more than award-winning spirits, offering an immersive guest experience. Named as one of the country’s Top Visitor Attractions by Whisky Magazine, guests can dine at their award-winning restaurant, enjoy show-stopping cocktails, learn about their highly awarded spirits with an in-depth tasting, and get an inside look at their active production facility. New to the distillery, guests have the opportunity to blend their own whiskey as they learn the inner workings of whiskey production.

Breckenridge Distillery is a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life.

To learn more about Breckenridge Distillery, visit www.breckenridgedistillery.com. Keep up with Breckenridge Distillery on Instagram by following @breckdistillery and become a fan at facebook.com/BreckDistillery. 

For more information about Tilray Brands, visit www.tilray.com and follow @tilray on Instagram, Twitter, Facebook, and LinkedIn.

Forward-Looking Statements

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.

For further information, please contact

Media: news@tilray.com
Investors: investors@tilray.com
Breckenridge Distillery: jessie.unruh@breckenridgedistillery.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/c5107390-6a4e-49c9-a6a6-5f845427c134

https://www.globenewswire.com/NewsRoom/AttachmentNg/209f298a-228f-4040-bd31-cf0762d63ba8

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.